Biocare Hepaguard Forte Vegetable - Pack of 60 Capsules

Product Information

Various interventions have been used in attempts to treat people with NAFLD, including nutritional supplementation (probiotics, prebiotics, synbiotics, vitamin supplementation, polyunsaturated fatty acid supplementation) ( Nabavi 2014; Sharifi 2014; Li 2015; Nogueira 2016; Mofidi 2017); lifestyle modifications such as dietary changes and exercise training (not included in this review) ( Abenavoli 2015; Shojaee‐Moradie 2016; Zhang 2016; Houghton 2017); pharmacological interventions (not included in this review) ( Lombardi 2017); and weight reduction surgery (bariatric surgery) (not included in this review) for obese people with NAFLD ( Adorini 2012; Anstee 2012; Chalasani 2012; Paschos 2012; Abenavoli 2013). When two or more interventions were combined, we considered this as a separate intervention ('node'). We collected data at maximum follow‐up but also at short term (up to three months) and at medium term (from three months to five years) if these were available. Nutritional supplementation has the potential to decrease liver damage, but whether this occurs is currently unclear.

No information is intended or implied to be a substitute for professional medical diagnosis or advice and should not be regarded as such. Definition used by study authors for serious adverse events and any adverse events ( ICH‐GCP 1997 versus other definitions).HepaGuard Forte is a specialist combination including choline bitartrate, inositol, sodium sulphate, artichoke extract, L-taurine, apple extract and L-methionine. It is a combination that includes choline bitartrate, inositol, sodium sulfate, artichoke extract, taurine, apple extract and L-methionine. We presented 'Summary of findings' tables for all primary and secondary outcomes (see Primary outcomes; Secondary outcomes). Phosphatidylcholine improves the absorption of silybine and thus promotes the natural regeneration of the liver.

A possible reason for complications of liver disease being rare in trial participants may be the short follow‐up period given in these trials (participants were followed only for a period of 2 months to 28 months). During this follow‐up period, clinical events related to NAFLD such as mortality, liver cirrhosis, liver decompensation, liver transplantation, hepatocellular carcinoma, and liver‐related mortality were sparse. The authors of this review collected and analysed all relevant randomised clinical trials with the aim of finding out what is the best treatment. When possible, we explored substantial clinical, methodological, or statistical heterogeneity and addressed the heterogeneity in subgroup analyses (see Subgroup analysis and investigation of heterogeneity). We planned to use standardised mean difference (SMD) values with 95% Crl for health‐related quality of life if included trials used different scales.A total of 138 trials were at low risk of performance bias, as participants and healthcare providers were blinded; 46 trials, which did not provide sufficient information, were at unclear risk of performance bias; the remaining 18 trials were at high risk of performance bias, as it is clear that either participants or healthcare providers, or both, were not blinded. Important characteristics, potential effect modifiers, and follow‐up for each trial are reported in Table 3. The size of the node (circle) provides a measure of the number of trials in which the particular Intervention was included as one of the intervention groups. A 'multiple parallel hits' model involving nutrition, gut bacteria, and accumulation of fat leading to liver inflammation has been proposed as an explanation for development and progression of NAFLD ( Tilg 2010; Buzzetti 2016). After a mean follow‐up period of 8 to 28 years, the presence of NAFLD was noted to increase overall long‐term mortality compared to the general population without NAFLD ( Adams 2005; Bedogni 2007; Ong 2008; Soderberg 2010; Onnerhag 2014).

gov), the outcomes sought should have been those enumerated in the original protocol if the trial protocol had been registered before or at the time the trial was begun. If it was not possible to calculate the standard deviation from the P value or from the confidence intervals, we planned to impute the standard deviation using the largest standard deviation in other trials for that outcome. The weighted median control group proportion shown in this table was from the only study in which a formal analysis was performed. We excluded 24 records (21 studies) for the reasons stated under Characteristics of excluded studies. We estimated the probability that each intervention was ranked at each of the possible positions based on estimated effect sizes and their corresponding uncertainty using the NICE DSU codes ( Dias 2016).HEPAGUARD is characterized by a specific action on the liver, increasing of the secretion of bile by the hepatocytes. in the vitamin E group developed cirrhosis and 0/83 (0%) in the no active intervention group developed decompensation.